I avoid thisdrug classwith bosutinib,nilotinib anddasatinibTKIs aremajorsubstratesfor this liverenzymeResponsewhen BCR-ABL1 (IS)is <0.01%I have theT315I mutationbut also haveelevated lipaseWhen togive H2RAswithdasatinibPatients havepresence of thisBCR-ABLproteinindicative ofCML Number ofblastspresent inacceleratedphaseToo many ofthese bloodcells areabnormal inCML60-70% ofpatients withCML presentwith thissymptomTreatmentfor blastphaseCMLAfter 3months, I have3% BCR-ABL,I have this TKIresponseThe scoringsystem usedin chronicphasePercentageof blastspresent inthe blastphaseTherecommendedcriteria usedfor acceleratedphaseThis TKI hasthe mostmetabolicsyndromeTranslocationbetweenthese twochromosomesoccur in CMLThe current5-yearoverallsurvival rateof CMLModerateto highemetogenicrisk TKIsNon-pharmacologicaltreatment forCMLDrug classthatrevolutionizedCMLtreatmentI want toavoid thisTKI if I donot wantdiarrheaThelandmarkfor thefirst TKII failed 3lines of TKIs,I can try thisagent nextThe numberof distinctclinicalphases inCMLI avoid thisdrug classwith bosutinib,nilotinib anddasatinibTKIs aremajorsubstratesfor this liverenzymeResponsewhen BCR-ABL1 (IS)is <0.01%I have theT315I mutationbut also haveelevated lipaseWhen togive H2RAswithdasatinibPatients havepresence of thisBCR-ABLproteinindicative ofCML Number ofblastspresent inacceleratedphaseToo many ofthese bloodcells areabnormal inCML60-70% ofpatients withCML presentwith thissymptomTreatmentfor blastphaseCMLAfter 3months, I have3% BCR-ABL,I have this TKIresponseThe scoringsystem usedin chronicphasePercentageof blastspresent inthe blastphaseTherecommendedcriteria usedfor acceleratedphaseThis TKI hasthe mostmetabolicsyndromeTranslocationbetweenthese twochromosomesoccur in CMLThe current5-yearoverallsurvival rateof CMLModerateto highemetogenicrisk TKIsNon-pharmacologicaltreatment forCMLDrug classthatrevolutionizedCMLtreatmentI want toavoid thisTKI if I donot wantdiarrheaThelandmarkfor thefirst TKII failed 3lines of TKIs,I can try thisagent nextThe numberof distinctclinicalphases inCML

Chronic Myeloid Leukemia BINGO - Call List

(Print) Use this randomly generated list as your call list when playing the game. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
I
2
I
3
B
4
N
5
G
6
B
7
O
8
N
9
G
10
I
11
I
12
B
13
B
14
N
15
O
16
G
17
I
18
G
19
O
20
N
21
B
22
G
23
O
24
O
  1. I-I avoid this drug class with bosutinib, nilotinib and dasatinib
  2. I-TKIs are major substrates for this liver enzyme
  3. B-Response when BCR-ABL1 (IS) is <0.01%
  4. N-I have the T315I mutation but also have elevated lipase
  5. G-When to give H2RAs with dasatinib
  6. B-Patients have presence of this BCR-ABL protein indicative of CML
  7. O-Number of blasts present in accelerated phase
  8. N-Too many of these blood cells are abnormal in CML
  9. G-60-70% of patients with CML present with this symptom
  10. I-Treatment for blast phase CML
  11. I-After 3 months, I have 3% BCR-ABL, I have this TKI response
  12. B-The scoring system used in chronic phase
  13. B-Percentage of blasts present in the blast phase
  14. N-The recommended criteria used for accelerated phase
  15. O-This TKI has the most metabolic syndrome
  16. G-Translocation between these two chromosomes occur in CML
  17. I-The current 5-year overall survival rate of CML
  18. G-Moderate to high emetogenic risk TKIs
  19. O-Non-pharmacological treatment for CML
  20. N-Drug class that revolutionized CML treatment
  21. B-I want to avoid this TKI if I do not want diarrhea
  22. G-The landmark for the first TKI
  23. O-I failed 3 lines of TKIs, I can try this agent next
  24. O-The number of distinct clinical phases in CML